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by Elsevier B.V. This is an open accesAbstract Pubertal gynaecomastia affects up to 70% of male adolescents, with the highest
prevalence occurring at 14 years of age. While spontaneous regression occurs in 90% of cases
within three years, until then, symptoms of mastodynia and psychological distress are preva-
lent in some patients prior to surgical treatment. Tamoxifen, a selective oestrogen receptor
modulator (SERM), given at 20 mg daily for six months, was found to be a safe, well-
tolerated and effective alternative treatment to current therapeutic options of watchful wait-
ing (no management) and invasive cosmetic surgery. No adverse effects were observed in hor-
monal and auxological studies. The patient presented was able to avoid undergoing surgery,
which should be reserved for persistent gynaecomastia present at the end of puberty after
failing a trial of tamoxifen. Randomised controlled trials (RCTs) are needed for definitive ther-
apeutic recommendations.
Copyright ª 2015, King Faisal Specialist Hospital & Research Centre (General Organization),
Saudi Arabia. Production and hosting by Elsevier B.V. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Gynaecomastia of adolescence is a common pubertal
occurrence and is often associated with persistent physical
discomfort and psychological distress in males. Many
treatment options have been proposed, ranging from
watchful waiting (no treatment), modification of hormonal4322 5436.
trics.com.au.
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al Specialist Hospital & Research C
s article under the CC BY-NC-NDaxes using medication and surgical intervention. The
following case discussion provides an overview of the con-
dition and describes the successful effect from using a six-
month course of tamoxifen, a Selective Oestrogen Receptor
Modulator (SERM), to treat pubertal gynaecomastia in a
typical teenage male.
2. Case report
A 14-year-old boy presented with unilateral left-sided
gynaecomastia present for the past twelve months
(Fig. 1). There was associated breast pain (mastodynia) of
5/10 severity, which was worse when wearing tight-fittingentre (General Organization), Saudi Arabia. Production and hosting
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 2 Side view of prominent left unilateral pubertal
gynaecomastia at baseline.
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conscious and being teased by peers in the locker room
had not been attending sports sessions. He had been
referred for suction lipectomy (liposuction) and was pre-
sented for pediatrician review for possible medical therapy
to avoid surgery.
The lesion measured 3 cm in diameter with marked
prominence (Fig. 2). A tender ‘disk’ of firm tissue was
palpable beneath the areolar region. The boy was not
overweight (body mass index (BMI) of 20.2, 60th centile) and
was in Tanner Stage 3 puberty (right testicular volume
10 mL, left 15 mL) with normal secondary sexual charac-
teristics for his age. He denied taking any regular medication
or having used any illicit substances, such as cannabis. There
was a positive family history of pubertal gynaecomastia in
his two older brothers, with one having had liposuction
performed. Blood tests showed a high normal testosterone
level (27 nmol/L), raised sex-hormone binding globulin
(SHBG) 93 nmol/L (normal range 15e50 nmol/L) and slightly
raised dehydroepiandrosterone sulphate (DHEAS) at 5 mmol/
L (normal range 0.1e4.2 mmol/L). Other indices were
normal; including a free androgen index (FAI) of 29%; oes-
tradiol: <50 pmol/L; prolactin: 305 mIU/L; quantitative
beta-human chorionic gonadotropin (b-hCG): <5 IU/L; folli-
cle stimulating hormone (FSH): 1.7 IU/L; luteinising hormone
(LH): 2.0 IU/L; and a full blood count, electrolytes and
karyotype (46 XY), excluding Klinefelter Syndrome.
3. Discussion
Pubertal gynaecomastia is a benign physiological process
arising from a transient imbalance between the greater
stimulatory effects of oestrogens and lesser inhibitory ef-
fects of androgens on breast tissue during puberty. It is
usually bilateral and affects up to 70% of adolescent males
[1], with a peak incidence at approximately 14 years of age
[2]. Oestrogen levels may become elevated from increased
peripheral aromatase activity (often occurring in the adi-
pose tissue of obese males and delaying puberty). This
increases the SHBG levels, which bind free (active)
testosterone, reducing its antitrophic action on breast
tissue. Glandular proliferation, ductal hyperplasia andFigure 1 Prominent unilateral pubertal gynaecomastia at
baseline. Left breast measures 3 cm [2].periductal inflammation occur as a result. This rapid
growth often occurs over the first six months of Tanner
Stage 3 puberty, when pubertal gynaecomastia is most
symptomatic (enlargement, pain and tenderness). While
pubertal gynaecomastia is a cosmetic condition and the
natural history is spontaneous regression in 90% of cases
within three years [3], it is frequently psychologically
distressing and causes embarrassment until it does so, with
some adolescents electing to undergo potentially dis-
figuring surgery [4].
Gynaecomastia is clinically defined by the presence of a
rubbery-to-firm disk-like mass that is often mobile, located
directly inferior to the areolar region and extending
concentrically from the nipple. It is distinct from pseudo-
gynaecomastia (or lipomastia), which is an adipose tissue
deposition without glandular proliferation, where no firm
mass is palpable. Histological examination of mastectomy
samples taken from males under 21 years of age for
adolescent gynaecomastia show the incidence of breast
cancer being extremely low [5]. The malignant lesion
invariably involves the unilateral breast; is often hard, fixed
and, eccentric; and may be associated with spontaneous
bloody nipple discharge, axillary lymphadenopathy or
overlying skin discolouration, dimpling or tethering (peau
d’orange). A family history of gynaecomastia is reported in
approximately 60% of cases [2]. The contributing factors for
gynaecomastia need to be considered. These include
hypogonadism, medication (notably antipsychotics,
including the newer atypical agents, such as risperidone, as
well as other drugs, for instance, spironolactone), alcohol,
marijuana or anabolic steroid use. In such cases, the
precipitating cause should be attended to first.
Three management options are available: (i) reassur-
ance (i.e., no treatment), (ii) surgery and (iii) medication.
The first is the safest option, although does not ameliorate
symptoms and is best for small, pain-free cases of recent
onset (<6 months). Surgery is usually a combination of
direct excision of the glandular tissue and liposuction.
Performing surgery is recommended after adult testicular
size (Tanner Stage 5 puberty) is attained, as there may be
regrowth of the breast tissue if performed earlier. Surgery
may also involve complications, such as scarring, skin
retraction and hyperaesthesia. Thus, it should be reserved
Figure 3 After 6 months of tamoxifen treatment. The left
breast now measures 2 cm [2] (33% reduction).
154 A. Zehetnerfor persistent cases, large and pendulous breasts unre-
sponsive to medical therapy, removing redundant tissue or
if significant fibrosis is present [6].
Medications aim to increase the effective androgen/
oestrogen imbalance and fall into three classes: (i) selec-
tive oestrogen receptor modulators, SERMs (tamoxifen and
raloxifene); (ii) aromatase inhibitors (anastrozole); and (iii)
androgens (for hypogonadism). Aromatase inhibitors block
the biosynthesis of oestrogen and have inferior results
compared to SERMs in clinical studies of the treatment of
pubertal gynaecomastia. SERMs block the growth-
stimulating effects of oestrogen on breast tissue, although
they are oestrogenic elsewhere in the body (bone and ad-
ipose tissues).
There have been no randomised controlled trials (RCTs)
of SERMs for the treatment of pubertal gynaecomastia,
and the medications are not registered for this indication
in Australia. While RCTs exist for the use of tamoxifen in
anti-androgen-induced gynaecomastia in adults treated
for prostatic cancer [7], it may be difficult to extrapolate
the clinical effect between these patient populations,
although the theoretical role of tamoxifen is sound. A
recent systematic review of tamoxifen therapy for the
management of pubertal gynaecomastia [8] found it to be
a safe and effective medical option. Doses of 10e40 mg of
tamoxifen per day were used in adolescent males under
the age of twenty for 1e12 months, with the resolution of
mastodynia and 80% reduction in swelling noted. The
response was dependent on the length of therapy, and
recurrence of gynaecomastia occurred in up to 14% of
cases after therapy cessation. SERMs appear to be most
effective within the first 6 months of gynaecomastia when
the breast tissue growth is most abundant and before
fibrosis occurs.
One observational study [2] has shown that tamoxifen
administered at a dose of 20 mg per day (as a single or
divided dose) for three months was a safe option in treating
pubertal gynaecomastia. Significant regression occurred in
approximately 90% of teenage boys, involving a mean
reduction in the breast nodule diameter of 2.1 cm (almost
half of the baseline diameter). Individuals with a smaller
breast diameter at baseline had a better outcome. Masto-
dynia was also reduced. The same study found similar and
slightly superior results with a different SERM, raloxifene.
However, as there is even less experience and available
data regarding the use of raloxifene for the treatment of
pubertal gynaecomastia than with tamoxifen; its current
use in clinical practice is limited.
Importantly, no clinically significant side-effects,
changes in the gonadotrophin levels or height during
treatment have been reported. Tamoxifen was well-
tolerated in the doses and duration used to treat pubertal
gynaecomastia in males [9]. While adverse events are rare,
tamoxifen use should be avoided in individuals with known
risk factors for venous thromboembolism and in the very
sedentary, as the potential for deep vein thrombosis (DVT)
exists. Any mood changes and leg cramps should be inves-
tigated. Occasional nausea and headaches may be
expected.
Breast tissue was found to regress spontaneously in up to
half of cases in trial control groups, so tamoxifen should be
used judiciously. Recurrence of gynaecomastia may occurin up to 25% cases after tamoxifen is ceased, so a further
course for six months may be indicated, as well as for non-
responders [2]. However, fewer individuals treated with
tamoxifen went on to have breast surgery, so its role in
surgery prevention is pivotal.
The boy in the case study was treated with tamoxifen,
20 mg per day, for six months. Within the first few weeks,
the patient’s mastodynia completely resolved and he
noticed that his left gynaecomastia began to reduce in size.
After three months, his body image satisfaction improved
and he resumed participation in sports involving being bare-
chested and changing in front of his peers. After six months,
the residual left breast was 2 cm in diameter (33% reduction
from baseline), flatter, without any palpable underlying
firm tissue and was symmetrical in size to the other breast
(Fig. 3). The boy did not report any adverse effects while
being treated with tamoxifen, consistent with the pub-
lished reports. Auxological parameters, including anthro-
pometry, growth velocity, progress pubertal staging, bone
age X-ray and repeat hormonal studies, were found to be
similar to the baseline values at the conclusion of treat-
ment (the testosterone level was 23.7 nmol/L; the SHBG
was 75 nmol/L, which was still elevated though less than
previously and could possibly indicate treatment resistance
and/or gynaecomastia recurrence on tamoxifen cessation;
the DHEAS was 5.6 mmol/L; the FAI was 31.6%; the FSH was
1.1 IU/L; the LH was 1.9 IU/L; and the oestradiol value was
70 pmol/L). This confirmed that tamoxifen therapy did not
adversely affect the hypogonadal pituitary axis in this
patient.
This case study demonstrates tamoxifen to be a safe,
well-tolerated and effective treatment option for male
pubertal gynaecomastia. It resolved mastodynia and
quickly reduced psychological distress by acting on the
cause of male pubertal gynaecomastia (blocking the action
of oestrogen-induced breast tissue proliferation). Tamox-
ifen treatment was more effective than previous months of
watchful waiting (no management). It was also a less
invasive treatment approach and reduced the need for
planned cosmetic surgery. An even greater effect of
tamoxifen therapy may have been observed if the patient
had received medical treatment earlier.
Tamoxifen to treat male pubertal gynaecomastia 155Tamoxifenmay be effective for the treatment of pubertal
gynaecomastia, and it seems to be safe according to the
many similar case reports. However, we need evidence from
randomised controlled trials (RCTs) to confirm these find-
ings. Until such results are known, tamoxifen should be used
on a judicial basis in carefully selected adolescent males
with pubertal gynaecomastia causing significant symptoms
(both physical and psychological), who are fully informed of
the risks and potential benefits (from available studies) and
who are considering surgical reduction procedures.
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AppendixKey learning points
 Pubertal gynaecomastia affects up to 70% of male
adolescents, peaking at 14 years of age
 Medication, drugs (e.g., cannabis), hypogonadism
and obesity are causative differential diagnoses
 Tamoxifen, a selective oestrogen receptor modu-
lator (SERM), appears to be a safe and effective
alternative treatment option in adolescent males
with significant symptoms considering surgery
 Randomised controlled trials (RCTs) are needed for
definitive therapeutic recommendations
 Surgery/liposuction should be reserved for persis-
tent cases present at the end of pubertyMultiple choice questions
1. Which individual is at the greatest risk of devel-
oping pubertal gynaecomastia?
a. An overweight 7-year-old boy whose father has
prostate cancer
b. A 12-year-old boy with growing pains from a recent
growth spurt who is medicated with olanzapine
c. A 17-year-old male who smokes 1 g of cannabis daily
d. A 13-year-old boy with XYY Syndrome and significant
facial acne
e. A 16-year-old boy on androgen replacement therapy
that shaves and has one alcoholic drink monthly at
parties
Answer: (b)
(a) An overweight child may exhibit pseudogynaecomas-
tia (or lipomastia) as an adolescent. Gynaecomastia
occurs in 10e20% of men treated with LHRH agonists
for prostate cancer, although this factor would not
affect the son.
(b) Increased growth velocity in boys usually occurs at
the onset of Tanner Stage 3 when pubertal gynae-
comastia also occurs. Antipsychotic medication,
including the newer second-generation atypical
agents, block dopamine and induce hyper-
prolactinaemia, causing gynaecomastia and/orgalactorrhoea, with risperidone being the most
frequently implicated medication.
(c) Pubertal gynaecomastia is uncommon in males over
17 years of age. Cannabis use has less effect on
gynaecomastia once puberty is completed, although
it may still have a deleterious effect on testosterone
levels and spermatogenesis.
(d) Boys with XYY Syndrome rarely have hypogonadism
and display gynaecomastia. This is more commonly
seen in Klinefelter syndrome (XXY). Significant facial
acne indicates virilisation and makes hypogonadism
less likely.
(e) A virilised adolescent male in mid-to-late puberty on
appropriate androgen replacement is unlikely to have
hypogonadism, as well as pubertal gynaecomastia,
based on age. Chronic alcohol use may reduce testos-
terone levels and induce gynaecomastia, although this
would not occur with mild, infrequent use.
2. Which one of the following statements best de-
scribes a typical clinical presentation of pubertal
gynaecomastia on palpation?
(a) A unilateral painful hard mass with axillary
lymphadenopathy
(b) Bilateral mobile and tender disc-like mounds of tissue
just beneath the nippleeareolar complex
(c) A mass associated with nipple discharge
(d) Multiple fixed peripheral masses with overlying skin
discolouration
(e) A dimpled appearance to the breast similar to an
orange peel
Answer: (b)
Pubertal gynaecomastia is often bilateral with the
proliferated breast tissue palpable, as described in
answer (b). Any lesion which is fixed, hard, peripher-
ally located and/or associated with lymphadenopathy
(a), discharge (c), skin discolouration (d) or tethering
(peau d’orange in answer (e)) should raise the suspi-
cion of breast cancer (invariably unilateral), and the
patient should be referred for mammography.
3. Which one of the following statements best de-
scribes treatment for pubertal gynaecomastia?
(a) Liposuction should be performed as early as possible
(b) Tamoxifen is effective, but produces serious adverse
effects
(c) Anastrozole is a superior medical therapy compared
to tamoxifen
(d) Tamoxifen may reduce the incidence of patients un-
dergoing gynaecomastia surgery
(e) Pharmacotherapy is most effective when instituted
after 12 months of watchful waiting
Answer: (d)
(a) Suction lipectomy (liposuction) should be performed
when puberty has been completed (Tanner Stage 5) as
there is a risk of gynaecomastia recurrence and
complication. As 90% of pubertal gynaecomastia will
resolve within three years, surgery should be reserved
for persistent cases, large and pendulous breasts un-
responsive tomedical therapy, for removing redundant
tissue or if a high degree of fibrosis is present.
156 A. Zehetner(b) Inmultiple studies using low doses and short treatment
courses for pubertal gynaecomastia, tamoxifen has
been well-tolerated without significant side effects.
Headache and nausea may be reported. A potential
risk of deep vein thrombosis (DVT) would preclude its
use in sedentary individuals or those at an increased
risk of venous thrombosis. This has not been reported
in the generally fit and active adolescents it has been
used in to date, who are at very low cardiovascular
risk. Any mood changes and leg cramps should be
investigated, as with adults taking tamoxifen.
(c) Aromatase inhibitors block the biosynthesis of oes-
trogen from testosterone and have been shown to be
inferior to Selective Oestrogen Receptor Modulators
(SERMs), such as tamoxifen, in clinical trials to treat
gynaecomastia.
(d) By reducing breast size andpain over the long term in
75% cases, patients treated with tamoxifen have less
need to undergo surgery for pubertal gynaecomastia.
(e) Watchful waiting is best for small, pain-free cases of
pubertal gynaecomastia of recent onset (<6 months).
Breast tissue growth is most abundant within the first
six months, and most symptoms occur during this
time. Medical therapy has the greatest effect when
initiated on large, painful lesions before six months
have elapsed. After 12 months, there is a higher
chance of breast tissue fibrosis and less response to
medical therapy.
References
[1] Bell DL, Breland DJ, Ott MA. Adolescent and young adult
male health: a review. Pediatrics 2013 Sep;132(3):535e46.http://dx.doi.org/10.1542/peds.2012-3414. Epub 2013 Aug
12.
[2] Lawrence SE, Faught KA, Vethamuthu J, Lawson ML. Beneficial
effects of raloxifene and tamoxifen in the treatment of pu-
bertal gynecomastia. J Pediatr 2004 Jul;145(1):71e6. http:
//dx.doi.org/10.1016/j.jpeds.2004.03.057.
[3] Khan HN, Blamey RW. Endocrine treatment of physiological
gynaecomastia. BMJ 2003 Aug 9;327(7410):301e2. http:
//dx.doi.org/10.1136/bmj.327.7410.301.
[4] Lemaine V, Cayci C, Simmons PS, Petty P. Gynecomastia in
adolescent males. Semin Plast Surg 2013;27(1):56e61. http:
//dx.doi.org/10.1055/s-0033-1347166.
[5] Koshy JC, Goldberg JS, Wolfswinkel EM, Ge Y, Heller L.
Breast cancer incidence in adolescent males undergoing
subcutaneous mastectomy for gynecomastia: is pathologic
examination justified? A retrospective and literature review.
Plast Reconstr Surg 2011 Jan;127(1):1e7. http:
//dx.doi.org/10.1097/PRS.0b013e3181f9581c.
[6] Cuhaci N, Polat SB, Evranos B, Ersoy R, Cakir B. Gynecomastia:
clinical evaluation and management. Indian J Endocrinol Metab
2014 Mar;18(2):150e8. http://dx.doi.org/10.4103/2230-
8210.129104.
[7] Kunath F, Keck B, Antes G, Wullich B, Meerpohl JJ. Tamoxifen
for the management of breast events induced by non-steroidal
antiandrogens in patients with prostate cancer: a systematic
review. BMC Med 2012;10:96. http://dx.doi.org/10.1186/1741-
7015-10-96.
[8] Lapid O, van Wingerden JJ, Perlemuter L. Tamoxifen ther-
apy for the management of pubertal gynecomastia: a sys-
tematic review. J Pediatr Endocr Met 2013;26(9e10):803e7.
http://dx.doi.org/10.1515/jpem-2013-0052.
[9] Maidment SL. Question 2. Which medications effectively
reduce pubertal gynaecomastia? Arch Dis Child 2010 Mar;95(3):
237e9. http://dx.doi.org/10.1136/adc.2009.176768.
